227 related articles for article (PubMed ID: 36315916)
1. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
[TBL] [Abstract][Full Text] [Related]
2. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
3. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
5. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
[TBL] [Abstract][Full Text] [Related]
6. Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
Trapani D; Crimini E; Sandoval J; Curigliano G
Cancer Treat Res; 2023; 188():343-351. PubMed ID: 38175352
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Bayle A; Belcaid L; Aldea M; Vasseur D; Peyraud F; Nicotra C; Geraud A; Sakkal M; Seknazi L; Cerbone L; Blanc-Durand F; Hadoux J; Mosele F; Tagliamento M; Bernard-Tessier A; Verret B; Smolenschi C; Clodion R; Auger N; Romano PM; Gazzah A; Camus MN; Micol J; Caron O; Hollebecque A; Loriot Y; Besse B; Lacroix L; Rouleau E; Ponce S; Soria JC; Barlesi F; Andre F; Italiano A
Ann Oncol; 2023 Apr; 34(4):389-396. PubMed ID: 36709039
[TBL] [Abstract][Full Text] [Related]
8. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
[TBL] [Abstract][Full Text] [Related]
9. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.
Colomer R; Miranda J; Romero-Laorden N; Hornedo J; González-Cortijo L; Mouron S; Bueno MJ; Mondéjar R; Quintela-Fandino M
EClinicalMedicine; 2023 Jun; 60():102029. PubMed ID: 37304496
[TBL] [Abstract][Full Text] [Related]
10. Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.
Melisi D; Cavaliere A; Gobbo S; Fasoli G; Allegrini V; Simionato F; Gaule M; Casalino S; Pesoni C; Zecchetto C; Merz V; Mambrini A; Barbi E; Girelli R; Giardino A; Frigerio I; Scalamogna R; Avitabile A; Castellani S; Milella M; Butturini G
Pancreatology; 2021 Apr; ():. PubMed ID: 33896692
[TBL] [Abstract][Full Text] [Related]
11. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
Tibau A; Hwang TJ; Molto C; Avorn J; Kesselheim AS
JAMA Oncol; 2024 May; 10(5):634-641. PubMed ID: 38573645
[TBL] [Abstract][Full Text] [Related]
12. Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results.
Lebedeva A; Timokhin G; Ignatova E; Kavun A; Veselovsky E; Sharova M; Mileyko V; Yakushina V; Kuznetsova O; Stepanova M; Shilo P; Moiseenko F; Volkov N; Plaksa I; Isaev A; Gayryan M; Artemyeva E; Zhabina A; Kramchaninov M; Shamrikova V; Pokataev I; Rumyantsev A; Ledin E; Tryakin A; Fedyanin M; Ivanov M
Clin Exp Med; 2023 Oct; 23(6):2663-2674. PubMed ID: 36752890
[TBL] [Abstract][Full Text] [Related]
13. Precision medicine in breast cancer: From clinical trials to clinical practice.
Crimini E; Repetto M; Aftimos P; Botticelli A; Marchetti P; Curigliano G
Cancer Treat Rev; 2021 Jul; 98():102223. PubMed ID: 34049187
[TBL] [Abstract][Full Text] [Related]
14. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
[TBL] [Abstract][Full Text] [Related]
15. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
Marret G; Bièche I; Dupain C; Borcoman E; du Rusquec P; Ricci F; Hescot S; Sablin MP; Tresca P; Bello D; Dubot C; Loirat D; Frelaut M; Lecerf C; Le Tourneau C; Kamal M
JCO Precis Oncol; 2021 Nov; 5():215-226. PubMed ID: 34994597
[TBL] [Abstract][Full Text] [Related]
16. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
[TBL] [Abstract][Full Text] [Related]
18. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
19. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Condorelli R; Mosele F; Verret B; Bachelot T; Bedard PL; Cortes J; Hyman DM; Juric D; Krop I; Bieche I; Saura C; Sotiriou C; Cardoso F; Loibl S; Andre F; Turner NC
Ann Oncol; 2019 Mar; 30(3):365-373. PubMed ID: 30715161
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
